Skip to content
2000
Volume 3, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Dermatophytes typically cause onychomycosis, which accounts for 50% of all nail diseases. Although formerly thought to be a cosmetic issue, it has recently gained attention because of its chronic nature and challenging treatment with relapses. Due to the lengthy treatment period and high expense associated with treating onychomycosis, numerous attempts have been made to overcome the hard nail barrier. Oral and topical medications are traditional treatments for onychomycosis. Despite their effectiveness, oral antifungal medications have hepatotoxic effects and can be mixed with other medications. Topical therapy improves patient compliance because it has no negative side effects. However, improper nail penetration poses a problem. Therefore, the goal of enhancing topical administration to effectively treat onychomycosis has been pursued for decades. Despite all efforts, issues with nail delivery have not been much closer to being resolved. Recently, the focus has shifted to novel drug delivery technologies, such as polymeric films, metallic nanoparticles, microemulsions, and nail lacquers, to enhance drug penetration and localized therapy. A global study is investigating their potential as efficacious treatment modalities. Thus, the goal of this review is to learn about innovative delivery methods for the treatment of onychomycosis, a persistent fungal disease.

© 2025 The Author(s).
© 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X347042250224060800
2025-01-01
2025-10-13

  • From This Site

    /content/journals/cis/10.2174/012210299X347042250224060800
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/3/1/CIS-3-E2210299X347042.html?itemId=/content/journals/cis/10.2174/012210299X347042250224060800&mimeType=html&fmt=ahah

References

  1. OsmariB.F. GiulianiL.M. ReolonJ.B. RigoG.V. TascaT. CruzL. Gellan gum-based hydrogel containing nanocapsules for vaginal indole-3-carbinol delivery in trichomoniasis treatment.Eur. J. Pharm. Sci.202015110537910.1016/j.ejps.2020.10537932473199
     [Google Scholar]
  2. Cutrín-GómezE. Conde-PenedoA. Anguiano-IgeaS. Gómez-AmozaJ.L. Otero-EspinarF.J. Optimization of drug permeation from 8% Ciclopirox Cyclodextrin/Poloxamer-soluble Polypseudorotaxane-based nail lacquers.Pharmaceutics202012323110.3390/pharmaceutics1203023132151015
     [Google Scholar]
  3. ThomasJ. PetersonG.M. ChristensonJ.K. KosariS. BabyK.E. Antifungal drug use for onychomycosis.Am. J. Ther.2019263e388e39610.1097/MJT.000000000000069631082864
     [Google Scholar]
  4. LeungAK LamJM LeongKF HonKL Tinea corporis: An updated review.Drugs Context. 202095610.7573/dic.2020‑5‑6
     [Google Scholar]
  5. FiroozA. ZamaniS. GhadreiA. AyatollahiA. TamimiP. KhamesipourA. Evaluation of efficacy and safety of topical nanoliposomal amphotericin B 0.4% gel as a potential treatment for onychomycosis: An interventional pilot clinical study.Dermatol. Ther. (Heidelb.)2023202319
     [Google Scholar]
  6. LipnerS.R. JosephW.S. VlahovicT.C. ScherR.K. RichP. GhannoumM. DanielC.R. ElewskiB. Therapeutic recommendations for the treatment of toenail onychomycosis in the US.J. Drugs Dermatol.202120101076108410.36849/JDD.629134636509
     [Google Scholar]
  7. GuptaAK SibbaldRG AndriessenA BelleyR BoroditskyA BotrosM Toenail Onychomycosis : A Canadian approach with a new transungual treatment: Development of a clinical pathway.J Cutan Med Surg.2015195440
     [Google Scholar]
  8. OlafssonJ.H. SigurgeirssonB. BaranR. Combination therapy for onychomycosis.Br. J. Dermatol.2003149s65Suppl. 65151810.1046/j.1365‑2133.149.s65.2.x14510971
     [Google Scholar]
  9. PolakA. The past, present and future of antimycotic combination therapy.Mycoses1999425-635537010.1046/j.1439‑0507.1999.00475.x10536428
     [Google Scholar]
  10. BaranR. KaoukhovA. Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy.J. Eur. Acad. Dermatol. Venereol.2005191212910.1111/j.1468‑3083.2004.00988.x15649187
     [Google Scholar]
  11. ElkeebR. AliKhanA. ElkeebL. HuiX. MaibachH.I. Transungual drug delivery: Current status.Int. J. Pharm.20103841-21810.1016/j.ijpharm.2009.10.00219819318
     [Google Scholar]
  12. GuptaA.K. GuptaG. JainH.C. LyndeC.W. FoleyK.A. DaigleD. CooperE.A. SummerbellR.C. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices.J. Eur. Acad. Dermatol. Venereol.20163091567157210.1111/jdv.1367727168494
     [Google Scholar]
  13. RatherS. KeenA. ShahF.Y. YaseenA. FarooqS. BakhshiA. Candidal Onychomycosis.Indian J. Dermatol.202166213213710.4103/ijd.IJD_395_2034188267
     [Google Scholar]
  14. GuptaA.K. JainH.C. LyndeC.W. MacDonaldP. CooperE.A. SummerbellR.C. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter Canadian survey of 15,000 patients.J. Am. Acad. Dermatol.200043224424810.1067/mjd.2000.10479410906646
     [Google Scholar]
  15. LooD.S. Onychomycosis in the Elderly.Drugs Aging200724429330210.2165/00002512‑200724040‑0000317432924
     [Google Scholar]
  16. BonattiJ.L.C. ScorzoniL. SingulaniJ.L. SantosC.T. NazaréA.C. ChorilliM. RegasiniL.O. Fusco-AlmeidaA.M. Mendes-GianniniM.J.S. Incorporation of Nonyl 3,4-Dihydroxybenzoate into nanostructured lipid systems: Effective alternative for maintaining anti-dermatophytic and antibiofilm activities and reducing toxicity at high concentrations.Front. Microbiol.202011115410.3389/fmicb.2020.0115432582096
     [Google Scholar]
  17. Del RossoJ.Q. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.J. Clin. Aesthet. Dermatol.201477101825053979
     [Google Scholar]
  18. LuxJ. DobiášR. KuklováI. LitvikR. ScholtzV. SouškováH. KhunJ. MrázekJ. KantorováM. JaworskáP. PrejdováT. ŠnupárkováJ. HamalP. JulákJ. Inactivation of dermatophytes causing onychomycosis and its therapy using non-thermal plasma.J. Fungi 20206421410.3390/jof604021433050542
     [Google Scholar]
  19. DavidB.G. ChetanaK. MenonR. RamyaM.R. Clinicomycological and histopathological profile of onychomycosis: A cross-sectional study from South India.Indian J. Dermatol.201964427227610.4103/ijd.IJD_160_1831516135
     [Google Scholar]
  20. GuptaA.K. Drummond-MainC. CooperE.A. BrintnellW. PiracciniB.M. TostiA. Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment.J. Am. Acad. Dermatol.201266349450210.1016/j.jaad.2011.02.03821820203
     [Google Scholar]
  21. HanH.W. HsuM.M.L. ChoiJ.S. HsuC.K. HsiehH.Y. LiH.C. ChangH.C. ChangT.C. Rapid detection of dermatophytes and Candida albicansin onychomycosis specimens by an oligonucleotide array.BMC Infect. Dis.201414158110.1186/s12879‑014‑0581‑525377491
     [Google Scholar]
  22. HoyN.Y. LeungA.K.C. MetelitsaA.I. AdamsS. New concepts in median nail dystrophy, onychomycosis, and hand, foot, and mouth disease nail pathology.ISRN Dermatol.201220121510.5402/2012/68016322462009
     [Google Scholar]
  23. CostaP.S. CruzE. VeigaF. JarrosI.C. NegriM. SvidzinskiT.I.E. Efficacy of propolis gel on mature biofilm formed by Neocosmospora keratoplastica isolated from onychomycosis.J. Fungi2022811121610.3390/jof811121636422037
     [Google Scholar]
  24. ThomasJ. JacobsonG.A. NarkowiczC.K. PetersonG.M. BurnetH. SharpeC. Review article: Toenail onychomycosis: An important global disease burden.J. Clin. Pharm. Ther.201035549751910.1111/j.1365‑2710.2009.01107.x20831675
     [Google Scholar]
  25. BongominF. BatacC.R. RichardsonM.D. DenningD.W. A review of onychomycosis due to Aspergillus species.Mycopathologia2018183348549310.1007/s11046‑017‑0222‑929147866
     [Google Scholar]
  26. HiroseM. NoguchiH. YaguchiT. MatsumotoT. HirumaM. FukushimaS. IhnH. Onychomycosis caused by Aspergillus subramanianii.J. Dermatol.201845111362136610.1111/1346‑8138.1461630144137
     [Google Scholar]
  27. DhuratR. SharmaR. A practical approach to the treatment of Alopecia Areata.Indian Dermatol. Online J.202213672572810.4103/idoj.idoj_176_2236386728
     [Google Scholar]
  28. GuptaA.K. StecN. Recent advances in therapies for onychomycosis and its management.F1000 Faculty Rev-9682019810.12688/f1000research.18646.1
     [Google Scholar]
  29. FarheenF. Updated perspectives on the diagnosis, management and novel drug delivery strategies for the treatment of onychomycosis.J Pharm Negat Results.202213812210.47750/Pnr.2022.13.S08.455
     [Google Scholar]
  30. GuptaA.K. MaysR.R. VersteegS.G. ShearN.H. PiguetV. Update on current approaches to diagnosis and treatment of onychomycosis.Expert Rev. Anti Infect. Ther.2018161292993810.1080/14787210.2018.154489130411650
     [Google Scholar]
  31. Navarro MorenoE Almagro LópezD Jaldo JiménezR Del Moral CampañaMC Árbol FernándezG Pérez RuizM Almagro NievasD Outbreak of hand, foot and mouth disease with onychomadesis caused by Coxsackie virus A16 in Granada.An Pediatr (Barc).201582423510.1016/j.anpedi.2014.05.015
     [Google Scholar]
  32. EichenfieldL.F. FriedlanderS.F. Pediatric onychomycosis: The emerging role of topical therapy.J. Drugs Dermatol.201716210510928300851
     [Google Scholar]
  33. YilmazA. GöktayF. VarolR. GencoglanG. UvetH. Deep convolutional neural networks for onychomycosis detection using microscopic images with KOH examination.Mycoses202265121119112610.1111/myc.1349835842749
     [Google Scholar]
  34. DabasY. XessI. SinghG. PandeyM. MeenaS. Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines.J. Fungi 2017321710.3390/jof302001729371535
     [Google Scholar]
  35. GiriY. HabibullahS. DixitP.K. MahalikG. MohantyB. BeheraA. Development of microemulgel formulations with varied permeation enhancers for transungual delivery of luliconazole in onychomycosis management.Colloids Surf. B Biointerfaces202423411371810.1016/j.colsurfb.2023.11371838176335
     [Google Scholar]
  36. LeungA.K.C. LamJ.M. LeongK.F. HonK.L. BarankinB. LeungA.A.M. WongA.H.C. Onychomycosis: An updated review.Recent Pat. Inflamm. Allergy Drug Discov.2020141324510.2174/1872213X1366619102609071331738146
     [Google Scholar]
  37. GuptaC. JongmanM. DasS. SnehaaK. BhattacharyaS.N. SeyedmousaviS. van DiepeningenA.D. Genotyping and in vitro antifungal susceptibility testing of fusarium isolates from onychomycosis in India.Mycopathologia20161817-849750410.1007/s11046‑016‑0014‑727138574
     [Google Scholar]
  38. FaloticoJ.M. LipnerS.R. Updated perspectives on the diagnosis and management of onychomycosis.Clin. Cosmet. Investig. Dermatol.2022151933195710.2147/CCID.S36263536133401
     [Google Scholar]
  39. BramonoK. BudimuljaU. Epidemiology of onychomycosis in Indonesia: Data obtained from three individual studies.Nippon Ishinkin Gakkai Zasshi200546317117610.3314/jjmm.46.17116094291
     [Google Scholar]
  40. ElewskiB.E. HayR.J. International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts.Pediatr. Dermatol.1996131697710.1111/j.1525‑1470.1996.tb01195.x8919533
     [Google Scholar]
  41. ElewskiB. HayR.J. International summit on cutaneous antifungal therapy. Boston, Massachusetts.Pediatr Dermatol.1994131697710.1111/j.1525‑1470.1996.tb01195.
     [Google Scholar]
  42. ElewskiB. HayR.J. International summit on cutaneous antifungal therapy. Boston, Massachusett.J. Am. Acad. Dermatol.1995335 Pt 181682210.1016/0190‑9622(95)91838‑87593783
     [Google Scholar]
  43. FikeJ.M. KolliparaR. AlkulS. StetsonC.L. Case report of onychomycosis and tinea corporis Due to Microsporum gypseum.J. Cutan. Med. Surg.2018221949610.1177/120347541772443928817957
     [Google Scholar]
  44. SigurgeirssonB. BaranR. The prevalence of onychomycosis in the global population: A literature study.J. Eur. Acad. Dermatol. Venereol.201428111480149110.1111/jdv.1232324283696
     [Google Scholar]
  45. PakshirK. KamaliM. NouraeiH. ZomorodianK. MotamediM. MahmoodiM. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis.Sci. Rep.20211112073610.1038/s41598‑021‑00104‑034671053
     [Google Scholar]
  46. ChristensonJ.K. PetersonG.M. NauntonM. BushellM. KosariS. BabyK.E. ThomasJ. Challenges and opportunities in the management of onychomycosis.J. Fungi2018438710.3390/jof403008730042327
     [Google Scholar]
  47. MonodM MéhulB. Recent findings in onychomycosis and their application for appropriate treatment.J Fungi 2019512010.3390/jof5010020
     [Google Scholar]
  48. MuthulathaA. TamilselvamB. ShanmugamS. PramodhiniS. Onychomycosis in onychodystrophy: A hospital-based clinico-mycological study.Int J Res Dermatol.20217342310.18203/issn.2455‑4529.IntJResDermatol20211703
     [Google Scholar]
  49. VeigaF.F. GadelhaM.C. da SilvaM.R.T. CostaM.I. KischkelB. de Castro-HoshinoL.V. SatoF. BaessoM.L. VoidaleskiM.F. Vasconcellos-PontelloV. VicenteV.A. BruschiM.L. NegriM. SvidzinskiT.I.E. Propolis extract for onychomycosis topical treatment: From bench to clinic.Front. Microbiol.2018977910.3389/fmicb.2018.0077929922236
     [Google Scholar]
  50. VlahovicT.C. GuptaA.K. Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.Expert Rev. Anti Infect. Ther.202220131510.1080/14787210.2021.193901134106031
     [Google Scholar]
  51. MontiD. MazzantiniD. TampucciS. VecchioneA. CelandroniF. BurgalassiS. GhelardiE. Ciclopirox and efinaconazole transungual permeation, antifungal activity, and proficiency to induce resistance in Trichophyton rubrum.Antimicrob. Agents Chemother.20196310e00442-1910.1128/AAC.00442‑1931332076
     [Google Scholar]
  52. ChularojanamontriL. PattanaprichakulP. LeeyaphanC. SuphatsathienkulP. WongdamaS. BunyaratavejS. Overall prevalence and prevalence compared among psoriasis treatments of onychomycosis in patients with nail psoriasis and fungal involvement.BioMed Res. Int.2021202111210.1155/2021/911341834938812
     [Google Scholar]
  53. Zalacain-VicuñaA.J. NietoC. PicasJ. MartínezH. BermejoR. CorralesA. CamposF.F. IgeaS.A. Otero-EspinarF.J. BrionesV.G.P. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.Mycoses202366756657510.1111/myc.1354336336989
     [Google Scholar]
  54. AkhtarN. SharmaH. PathakK. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals.Scientifica (Cairo)2016201611210.1155/2016/138793627123362
     [Google Scholar]
  55. QuellerJ. BhatiaN. The dermatologist’s approach to onychomycosis.J. Fungi 20151217318410.3390/jof102017329376907
     [Google Scholar]
  56. ChauhanA. NainwalN. ButolaM. JakhmolaV. Exhaustive review on nail lacquer in the treatment of nail diseases.Philipp. J. Sci.2023152510.56899/152.05.30
     [Google Scholar]
  57. PetrucelliM.F. AbreuM.H. CantelliB.A.M. SeguraG.G. NishimuraF.G. BitencourtT.A. MarinsM. FachinA.L. Epidemiology and diagnostic perspectives of dermatophytoses.J. Fungi20206431010.3390/jof604031033238603
     [Google Scholar]
  58. MatsudaY. SugiuraK. HashimotoT. UedaA. KonnoY. TatsumiY. Efficacy coefficients determined using nail permeability and antifungal activity in keratin-containing media are useful for predicting clinical efficacies of topical drugs for onychomycosis.PLoS One2016117e015966110.1371/journal.pone.015966127441843
     [Google Scholar]
  59. SeoM.R. KimH.S. LeeY.B. ShinS. ChungY.J. Rapid and specific detection of Trichophyton rubrum and Trichophyton mentagrophytes using a loop-mediated isothermal amplification assay.MethodsX2022910189110.1016/j.mex.2022.10189136353357
     [Google Scholar]
  60. SanerM.V. KulkarniA.D. PardeshiC.V. Insights into drug delivery across the nail plate barrier.J. Drug Target.201422976978910.3109/1061186X.2014.92913824964054
     [Google Scholar]
  61. HafeezF. HuiX. ChiangA. HornbyS. MaibachH. Transungual delivery of ketoconazole using novel lacquer formulation.Int. J. Pharm.2013456235736110.1016/j.ijpharm.2013.08.08224029171
     [Google Scholar]
  62. IermakI. da SilvaA.P. KurachiC. BagnatoV.S. InadaN.M. Raman microspectroscopy as a tool to elucidate the efficacy of topical formulations containing curcumin.Pharmaceuticals20191214410.3390/ph1201004430909531
     [Google Scholar]
  63. GuptaA.K. VersteegS.G. ShearN.H. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment.J. Cutan. Med. Surg.201721652553910.1177/120347541771636228639462
     [Google Scholar]
  64. GuptaA.K. FleckmanP. BaranR. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.J. Am. Acad. Dermatol.2000434Suppl.S70S8010.1067/mjd.2000.10907111051136
     [Google Scholar]
  65. BsiesoE.A. NasrM. MoftahN.H. SammourO.A. Abd El GawadN.A. Could nanovesicles containing a penetration enhancer clinically improve the therapeutic outcome in skin fungal diseases?Nanomedicine201510132017203110.2217/nnm.15.4926135513
     [Google Scholar]
  66. BaranR. SigurgeirssonB. BerkerD. KaufmannR. LechaM. FaergemannJ. KerroucheN. SidouF. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.Br. J. Dermatol.2007157114915710.1111/j.1365‑2133.2007.07974.x17553051
     [Google Scholar]
  67. PannuJ. McCarthyA. MartinA. HamoudaT. CiottiS. FothergillA. SutcliffeJ. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans.Antimicrob. Agents Chemother.20095383273327910.1128/AAC.00218‑0919433562
     [Google Scholar]
  68. GhannoumM. IshamN. HerbertJ. HenryW. YurdakulS. Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.J. Clin. Microbiol.20114951716172010.1128/JCM.00083‑1121411586
     [Google Scholar]
  69. SoaresL.A. GulloF.P. SardiJ.C.O. PitanguiN.S. Costa-OrlandiC.B. Sangalli-LeiteF. ScorzoniL. RegasiniL.O. PetrônioM.S. SouzaP.F. SilvaD.H.S. Mendes-GianniniM.J.S. Fusco-AlmeidaA.M. Anti-trichophyton activity of protocatechuates and their synergism with fluconazole.Evid. Based Complement. Alternat. Med.20142014195786010.1155/2014/95786025136374
     [Google Scholar]
  70. ZhouX. LianH. LiH. FanM. XuW. JinY. Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.Front. Pharmacol.202213106579310.3389/fphar.2022.106579336588709
     [Google Scholar]
  71. TarannumN. PoojaK. JakharS. MaviA. Nanoparticles assisted intra and transdermic delivery of antifungal ointment: An updated review.Discover Nano.20241911110.1186/s11671‑023‑03932‑338195832
     [Google Scholar]
  72. FloresF.C. de LimaJ.A. RibeiroR.F. AlvesS.H. RolimC.M. BeckR.C. da SilvaC.B. Antifungal activity of nanocapsule suspensions containing tea tree oil on the growth of Trichophyton rubrum.Mycopathologia20131753-428128610.1007/s11046‑013‑9622‑723392821
     [Google Scholar]
  73. WingSin Chiu BelseyN.A. GarrettN.L. MogerJ. PriceG.J. Delgado-CharroM.B. GuyR.H. Drug delivery into microneedle-porated nails from nanoparticle reservoirs.J. Control. Release2015220Part A9810610.1016/j.jconrel.2015.10.026
     [Google Scholar]
  74. WangF. YangP. ChoiJ.S. AntovskiP. ZhuY. XuX. KuoT.H. LinL.E. KimD.N.H. HuangP.C. XuH. LeeC.F. WangC. HsuC.C. ChenK. WeissP.S. TsengH.R. Cross-linked fluorescent supramolecular nanoparticles for intradermal controlled release of antifungal drug-a therapeutic approach for onychomycosis.ACS Nano20181276851685910.1021/acsnano.8b0209929851454
     [Google Scholar]
  75. MahtabA. AnwarM. MallickN. NazZ. JainG. AhmadF. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis.AAPS PharmSciTech20161710.1208/s12249‑016‑0488‑0
     [Google Scholar]
  76. ElsherifN.I. ShammaR.N. AbdelbaryG. Terbinafine hydrochloride trans-ungual delivery via nanovesicular systems: In vitro characterization and ex vivo evaluation.AAPS PharmSciTech201718255156210.1208/s12249‑016‑0528‑927138036
     [Google Scholar]
  77. PhagnaM. BadhwarR. SinghM. AlhalmiA. KhanR. NomanO.M. AlahdabA. Development and characterization of terbinafine-loaded nanoemulgel for effective management of dermatophytosis.Gels202391189410.3390/gels911089437998984
     [Google Scholar]
  78. Tuncay TanrıverdiS. Hilmioğlu PolatS. Yeşim MetinD. KandiloğluG. ÖzerÖ. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: In vitro and in vivo evaluation.J. Liposome Res.201626216317310.3109/08982104.2015.106789226226352
     [Google Scholar]
  79. BarotB.S. ParejiyaP.B. PatelH.K. MehtaD.M. ShelatP.K. Microemulsion-based antifungal gel delivery to nail for the treatment of onychomycosis: Formulation, optimization, and efficacy studies.Drug Deliv. Transl. Res.20122646347610.1007/s13346‑012‑0109‑825787325
     [Google Scholar]
  80. KansagraH. MallickS. Microemulsion-based antifungal gel of luliconazole for dermatophyte infections: Formulation, characterization and efficacy studies.J. Pharm. Investig.201546212810.1007/s40005‑015‑0209‑9
     [Google Scholar]
  81. ShuklaT. UpmanyuN. AgrawalM. SarafS. SarafS. AlexanderA. Biomedical applications of microemulsion through dermal and transdermal route.Biomed. Pharmacother.2018108September1477149410.1016/j.biopha.2018.10.02130372850
     [Google Scholar]
  82. AlmuqbilR.M. SreeharshaN. NairA.B. Formulation-by-design of efinaconazole spanlastic nanovesicles for transungual delivery using statistical risk management and multivariate analytical techniques.Pharmaceutics2022147141910.3390/pharmaceutics1407141935890316
     [Google Scholar]
  83. Nogueiras-NietoL. Begoña Delgado-CharroM. Otero-EspinarF.J. Thermogelling hydrogels of cyclodextrin/poloxamer polypseudorotaxanes as aqueous-based nail lacquers: Application to the delivery of triamcinolone acetonide and ciclopirox olamine.Eur. J. Pharm. Biopharm.201383337037710.1016/j.ejpb.2012.11.00423201053
     [Google Scholar]
  84. ElsherifN. ShammaR. AbdelbaryG. In-situ gels and nail lacquers as potential delivery systems for treatment of onychomycosis. A comparative study.J. Drug Deliv. Sci. Technol.20174310.1016/j.jddst.2017.10.018
     [Google Scholar]
  85. Abd-ElsalamW.H. AbouelattaS.M. Contemporary techniques and potential transungual drug delivery nanosystems for the treatment of onychomycosis.AAPS PharmSciTech202324615010.1208/s12249‑023‑02603‑x37421509
     [Google Scholar]
  86. DaryabM. FaiziM. MahboubiA. AboofazeliR. Preparation and characterization of lidocaine-loaded, microemulsion-based topical gels.Iran. J. Pharm. Res.2022211e12378710.5812/ijpr.12378735765506
     [Google Scholar]
  87. McAuleyW.J. JonesS.A. TraynorM.J. GuesnéS. MurdanS. BrownM.B. An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates.Eur. J. Pharm. Biopharm.201610217818410.1016/j.ejpb.2016.03.00826969264
     [Google Scholar]
  88. AdekhandiS. PalS. SharmaN. JuyalD. SharmaM. DimriD. Incidence and epidemiology of onychomycosis in patients visiting a tertiary care hospital in India.Cutis2015951E20E2525671453
     [Google Scholar]
  89. GhannoumM. IshamN. Fungal nail infections (onychomycosis): A never-ending story?PLoS Pathog.2014106e100410510.1371/journal.ppat.100410524901242
     [Google Scholar]
  90. KushwahaA. MurthyR.N. MurthyS.N. ElkeebR. HuiX. MaibachH.I. Emerging therapies for the treatment of ungual onychomycosis.Drug Dev. Ind. Pharm.201541101575158110.3109/03639045.2015.103342625997365
     [Google Scholar]
  91. RochaK.A.D. Krawczyk-SantosA.P. AndradeL.M. SouzaL.C. MarretoR.N. GratieriT. TaveiraS.F. Voriconazole-loaded nanostructured lipid carriers (NLC) for drug delivery in deeper regions of the nail plate.Int. J. Pharm.2017531129229810.1016/j.ijpharm.2017.08.11528859937
     [Google Scholar]
  92. ShahV.H. JobanputraA. Enhanced Ungual permeation of terbinafine HCl delivered through liposome-loaded nail lacquer formulation optimized by QbD approach.AAPS PharmSciTech201819121322410.1208/s12249‑017‑0831‑028681334
     [Google Scholar]
  93. FloresF.C. RossoR.S. CruzL. BeckR.C.R. SilvaC.B. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment.Eur. J. Pharm. Sci.2017100566310.1016/j.ejps.2016.12.04328063967
     [Google Scholar]
  94. FerrariJ. Fungal toenail infections.Clin. Evid.20112011171521846413
     [Google Scholar]
  95. FaloticoJ.M. LapidesR. LipnerS.R. Combination therapy should be reserved as second-line treatment of onychomycosis: A systematic review of onychomycosis clinical trials.J. Fungi20228327910.3390/jof803027935330281
     [Google Scholar]
  96. Marcos-TejedorF. Santos-CarniceroN. MayordomoR. Preliminary evidence of the efficacy of nitric acid treatment in onychomycosis.Int. J. Environ. Res. Public Health202118241337110.3390/ijerph18241337134948980
     [Google Scholar]
  97. DarkesM.J.M. ScottL.J. GoaK.L. Terbinafine.Am. J. Clin. Dermatol.200341396510.2165/00128071‑200304010‑0000512477372
     [Google Scholar]
  98. YinZ. XuJ. LuoD. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole.J. Dermatolog. Treat.201223644945210.3109/09546634.2011.57908221801094
     [Google Scholar]
  99. AzambujaC.V. PimmelL.A. KlafkeG.B. XavierM.O. Onychomycosis: Clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum.An Bras Dermatol.201489458110.1590/abd1806‑4841.20142630
     [Google Scholar]
  100. TrivediN.A. ShahP.C. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis.Indian J. Dermatol.201055219819910.4103/0019‑5154.6274620606897
     [Google Scholar]
  101. KortingHC SchöllmannC The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes.J. Dtsch. Dermatol. Ges.2009711110.1111/j.1610‑0387.2008.06751.x
     [Google Scholar]
  102. TabaraK. SzewczykA.E. BieniasW. WojciechowskaA. PastuszkaM. OszukowskaM. KaszubaA. Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis.Postepy Dermatol. Alergol.201511404510.5114/pdia.2014.4096825821426
     [Google Scholar]
  103. ReinelD. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: Comparative efficacy and tolerability of once and twice weekly use.Dermatology19921841212410.1159/0002476121532336
     [Google Scholar]
  104. IorizzoM. HartmaneI. DervenieceA. MikazansI. Ciclopirox 8% HPCH Nail lacquer in the treatment of mild-to-moderate onychomycosis: A randomized, double-blind amorolfine controlled study using a blinded evaluator.Skin Appendage Disord.20151313414010.1159/00044156927171791
     [Google Scholar]
  105. UlbrichtH WörzK. Therapy with ciclopirox lacquer of onychomycoses caused by molds.Mycoses199437197100
     [Google Scholar]
  106. DarsS. BanwellH.A. MatriccianiL. The use of urea for the treatment of onychomycosis: A systematic review.J. Foot Ankle Res.20191212210.1186/s13047‑019‑0332‑331007722
     [Google Scholar]
  107. PandhiD. VermaP. Nail avulsion: Indications and methods (surgical nail avulsion).Indian J. Dermatol. Venereol. Leprol.201278329930810.4103/0378‑6323.9544422565429
     [Google Scholar]
  108. Di ChiacchioN. KaduncB.V. De AlmeidaA.R.T. MadeiraC.L. Nail abrasion.J. Cosmet. Dermatol.200323-415015210.1111/j.1473‑2130.2004.00095.x17163921
     [Google Scholar]
  109. AngeloT. Borgheti-CardosoL.N. GelfusoG.M. TaveiraS.F. GratieriT. Chemical and physical strategies in onychomycosis topical treatment: A review.Med. Mycol.2016555myw08410.1093/mmy/myw08427703019
     [Google Scholar]
  110. ChenK. PuriV. Michniak-KohnB. Iontophoresis to overcome the challenge of nail permeation: Considerations and optimizations for successful ungual drug delivery.AAPS J.20212312510.1208/s12248‑020‑00552‑y33439400
     [Google Scholar]
  111. KushwahaA. ShivakumarH.N. MurthyS.N. Iontophoresis for drug delivery into the nail apparatus: Exploring hyponychium as the site of delivery.Drug Dev. Ind. Pharm.201642101678168210.3109/03639045.2016.116569026981643
     [Google Scholar]
  112. SharmaS. ChopraH. PahwaR. EmranT.B. SinghI. Novel transungual drug delivery system for treating onychomycosis.Int. J. Surg.2023Publish Ahead of Print72145214710.1097/JS9.000000000000004136906788
     [Google Scholar]
  113. GuptaA.K. SimpsonF.C. New therapeutic options for onychomycosis.Expert Opin. Pharmacother.20121381131114210.1517/14656566.2012.68177922533461
     [Google Scholar]
  114. MuralidharP. Transungual drug delivery.Int. J. Pharma. Res. Health. Sci.201751522152810.21276/ijprhs.2017.01.01
     [Google Scholar]
  115. SimmonsB.J. GriffithR.D. Falto-AizpuruaL.A. NouriK. An update on photodynamic therapies in the treatment of onychomycosis.J. Eur. Acad. Dermatol. Venereol.20152971275127910.1111/jdv.1295025589056
     [Google Scholar]
  116. BhattaA.K. KeyalU. WangX.L. Photodynamic therapy for onychomycosis: A systematic review.Photodiagn. Photodyn. Ther.20161522823510.1016/j.pdpdt.2016.07.01027477248
     [Google Scholar]
  117. Kline-SchoderA. LeZ. ZdericV. Ultrasound-enhanced ciclopirox delivery for treatment of onychomycosis.Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.201820185717572010.1109/EMBC.2018.851355230441634
     [Google Scholar]
  118. Kline-SchoderA. LeZ. ZdericV. Ultrasound‐enhanced drug delivery for treatment of onychomycosis.J. Ultrasound Med.20183771743175210.1002/jum.1452629288596
     [Google Scholar]
  119. AbadiD. ZdericV. Ultrasound-mediated nail drug delivery system.J. Ultrasound Med.201130121723173010.7863/jum.2011.30.12.172322124008
     [Google Scholar]
/content/journals/cis/10.2174/012210299X347042250224060800
Loading
Updated Assessment of Drug Delivery Techniques for the Treatment of Onychomycosis
Curr. Indian Sci. 3, e2210299X347042 (2025); https://doi.org/10.2174/012210299X347042250224060800
/content/journals/cis/10.2174/012210299X347042250224060800
/content/journals/cis/10.2174/012210299X347042250224060800
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Dermatophytes; Drug delivery; Fungal infection; Onychomycosis; Pathogenesis; Topical transport

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test